🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prediction of Cerebral Hyperperfusion Syndrome After Carotid Revascularization Using Deep Learning

Recruitingn/aAges 30 Years - 80 YearsAllState Institution "Republican Scientific and Prac…
NCT05800821 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Cerebral hyperperfusion syndrome (CHS) was initially described as a clinical complication following carotid endarterectomy (CEA), but it may occur after both CEA and carotid artery stenting. It is characterised by throbbing ipsilateral frontotemporal or periorbital headache, and sometimes diffuse headache, eye and facial pain, vomiting, confusion, macular oedema, visual disturbances, focal motor seizures with frequent secondary generalisation, focal neurological deficits, and intracerebral or subarachnoid haemorrhage. Knowledge of CHS among physicians remains limited. Most studies report an incidence of 1-3% after carotid endarterectomy. CHS is most common in patients with increases of more than 100% in cerebral perfusion compared with baseline after carotid revascularization, and is rare in patients with perfusion increases of less than 100% compared with baseline. The pathophysiologi

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Age between 30 and 80 years. 2. Occlusive-stenotic lesion of the carotid arteries with indications for carotid revascularization. Exclusion Criteria: 1. Systemic vasculitis. 2. Cerebral vessel aneurysms. 3. Arteriovenous malformation of the brain. 4. Primary brain tumor (including metastatic lesions). 5. Epilepsy. 6. History of traumatic brain injury. 7. Demyelinating diseases of the central nervous system. 8. History of neuroinfection. 9. Atrial fibrillation. 10. Frequent supraventricular or ventricular extrasystoles. 11. Chronic heart failure with left ventricular ejection fraction less than 40%. 12. Chronic kidney disease with estimated glomerular filtration rate less than 45 mL/min/1.73 m². 13. Presence of an implanted cardioverter-defibrillator or pacemaker. 14. Presence of contraindications to the medical use of iodine-containing radiographic contrast agents. 15. Patient's unwillingness to continue participating in the study. 16. Absence of a temporal acoustic window for transcranial Doppler ultrasonography.
💊

What it tests

  • Carotid revascularization
📍

Where

1 site
State Institution "Republican Scientific and Practical Center "Cardiology"
Minsk, Belarus
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy